Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Medical Oncology
Published in: Medical Oncology 5/2024

01-05-2024 | Hematologic Cancer | Review Article

Investigating the correlation between prominent viruses and hematological malignancies: a literature review

Authors: Arian Haghtalab, Milad Hejazi, Naeem Goharnia, Ali Yekanlou, Kousha Hazhir, Asma Barghi, Zahra Bazzaz, Iman Allahverdizadeh, Ataollah GhalibafSabbaghi

Published in: Medical Oncology | Issue 5/2024

Login to get access

Abstract

Extensive research has been conducted on the correlation between viral infections and hematological cancers ever since the identification of the Rous Sarcoma Virus as a cancer-causing agent. Numerous viruses, such as the Epstein-Barr virus, hepatitis B virus, hepatitis C virus, human immunodeficiency virus, human T-lymphotropic virus 1, and severe acute respiratory syndrome-related coronavirus 2, have been identified as potential contributors to the development and progression of cancer by disrupting normal cellular processes. Different viruses are associated with distinct forms of blood cancers, each exhibiting unique infection mechanisms, pathogenesis, and clinical symptoms. Understanding these connections is crucial for the development of effective prevention and treatment strategies. Healthcare professionals who possess a solid understanding of these associations can offer precise treatments and closely monitor potential complications in individuals with blood cancers and viral infections. By leveraging this information, healthcare providers can optimize patient care and improve outcomes for those affected by both viral infections and hematological cancers.
Literature
1.
2.
The Nobel Prize in Physiology or Medicine 1966. https://​nobelprizeorg/​prizes/​medicine/​1966/​rous/​facts/​.​
3.
Meléndez LV, Hunt RD, Daniel MD, García FG, Fraser CE. Herpesvirus saimiri. II. Experimentally induced malignant lymphoma in primates. Lab Animal Care. 1969;19(3):378–86.
4.
Diamandopoulos GT. Induction of lymphocytic leukemia, lymphosarcoma, reticulum cell sarcoma, and osteogenic sarcoma in the syrian golden hamster by oncogenic DNA simian virus 402. J Natl Cancer Institute. 1973;50(5):1347–65.CrossRef
5.
6.
Bryan ES, Prasanna T. Human T Cell Lymphotropic Virus. Nihgov. 2022.
7.
8.
9.
Silling S, Kreuter A, Gambichler T, Meyer T, Stockfleth E, Wieland U. Epidemiology of merkel cell polyomavirus infection and merkel cell carcinoma. Cancers. 2022;14(24):6176.PubMedPubMedCentralCrossRef
10.
11.
About Epstein-Barr Virus (EBV) | CDC. wwwcdcgov. 2022.
12.
Epstein MA, Achong BG, Barr YM. Virus particles in cultured lymphoblasts from burkitt’s lymphoma. The Lancet. 1964;283(7335):702–3.CrossRef
13.
Womack J, Jimenez M. Common questions about infectious mononucleosis. Am Fam Physician. 2015;91(6):372–6.PubMed
14.
Grotto I, Mimouni D, Huerta M, Mimouni M, Cohen D, Robin G, et al. Clinical and laboratory presentation of EBV positive infectious mononucleosis in young adults. Epidemiol Infect. 2003;131(1):683–9.PubMedPubMedCentralCrossRef
15.
Mayo C. Mononucleosis - Symptoms and causes. Mayo Clinic. 2018.
16.
Tattevin P, Le Tulzo Y, Minjolle S, Person A, Chapplain JM, Arvieux C, et al. Increasing incidence of severe Epstein-Barr virus-related infectious mononucleosis: surveillance study. J Clin Microbiol. 2006;44(5):1873–4.PubMedPubMedCentralCrossRef
17.
18.
Son KH, Shin MY. Clinical features of Epstein-Barr virus-associated infectious mononucleosis in hospitalized Korean children. Korean J Pediatr. 2011;54(10):409.PubMedPubMedCentralCrossRef
19.
Topp SK, Rosenfeldt V, Vestergaard H, Christiansen CB, Von Linstow M-L. Clinical characteristics and laboratory findings in Danish children hospitalized with primary Epstein-Barr virus infection. Infect Dis. 2015;47(12):908–14.CrossRef
20.
Medovic R, Igrutinovic Z, Radojevic-Marjanovic R, Markovic S, Raskovic Z, Simovic A, et al. Clinical and laboratory differences between Epstein-Barr and cytomegalovirus infectious mononucleosis in children. Srp Arh Celok Lek. 2016;144(1–2):56–62.PubMedCrossRef
21.
Çağlar İ, Topal S, Çokboz M, Düzgöl M, Kara A, Bayram SN, et al. Clinical features and laboratory findings in children hospitalized with acute epstein-barr virus infection: a crosssectional study in a tertiary care hospital. Turk J Pediatr. 2019;61(3):368.PubMedCrossRef
22.
23.
Molyneux EM, Rochford R, Griffin B, Newton R, Jackson G, Menon G, et al. Burkitt’s lymphoma. The Lancet. 2012;379(9822):1234–44.CrossRef
24.
Massini G, Siemer D, Hohaus S. EBV in hodgkin lymphoma. Mediterranean J Hematol Infect Dis. 2009;1(2): e2009013.
25.
Goudarzipour K, Kajiyazdi M, Mahdaviyani A. Epstein-Barr virus-induced hemophagocytic lymphohistiocytosis. Int J Hematol-Oncol Stem Cell Res. 2013;7(1):42–5.PubMedPubMedCentral
26.
27.
Thida AM, Gohari P. Extranodal NK-Cell Lymphoma. PubMed. 2022.
28.
29.
Ng S-B, Chung T-H, Kato S, Nakamura S, Takahashi E, Ko Y-H, et al. Epstein-Barr virus-associated primary nodal T/NK-cell lymphoma shows a distinct molecular signature and copy number changes. Haematologica. 2017;103(2):278–87.PubMedCrossRef
30.
Schinzari V, Barnaba V, Piconese S. Chronic hepatitis B virus and hepatitis C virus infections and cancer: synergy between viral and host factors. Clin Microbiol Infect. 2015;21(11):969–74.PubMedCrossRef
31.
Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastroenterol Hepatol. 2018;3(6):383–403.
32.
Kao JH, Chen DS. Global control of hepatitis B virus infection. Lancet Infect Dis. 2002;2(7):395–403.PubMedCrossRef
33.
Wilkins T, Sams R, Carpenter M. Hepatitis B: Screening, prevention, diagnosis, and treatment. Am Fam Physician. 2019;99(5):314–23.PubMed
34.
Summers J, Mason WS. Replication of the genome of a hepatitis B–like virus by reverse transcription of an RNA intermediate. Cell. 1982;29(2):403–15.PubMedCrossRef
35.
Seeger C, Mason WS. Molecular biology of hepatitis B virus infection. Virology. 2015;479–480:672–86.PubMedCrossRef
36.
Terrault NA, Bzowej NH, Chang KM, Hwang JP, Jonas MM, Murad MH. AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2016;63(1):261–83.PubMedCrossRef
37.
Yeo W, Johnson PJ. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology. 2006;43(2):209–20.PubMedCrossRef
38.
Raimondo G, Allain JP, Brunetto MR, Buendia MA, Chen DS, Colombo M, et al. Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol. 2008;49(4):652–7.PubMedCrossRef
39.
Bréchot C. Pathogenesis of hepatitis B virus-related hepatocellular carcinoma: old and new paradigms. Gastroenterology. 2004;127(5 Suppl 1):S56-61.PubMedCrossRef
40.
Raimondo G, Caccamo G, Filomia R, Pollicino T. Occult HBV infection. Semin Immunopathol. 2013;35(1):39–52.PubMedCrossRef
41.
Rossi D, Sala L, Minisini R, Fabris C, Falleti E, Cerri M, et al. Occult hepatitis B virus infection of peripheral blood mononuclear cells among treatment-naive patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2009;50(4):604–11.PubMedCrossRef
42.
Wang C, Xia B, Ning Q, Zhao H, Yang H, Zhao Z, et al. High prevalence of hepatitis B virus infection in patients with aggressive B cell non-Hodgkin’s lymphoma in China. Ann Hematol. 2018;97(3):453–7.PubMedCrossRef
43.
Pinato DJ, Rossi D, Minh MT, Toniutto P, Boccato E, Minisini R, et al. Hepatitis B virus and lymphomagenesis: novel insights into an occult relationship. Dig Liver Dis. 2012;44(3):235–8.PubMedCrossRef
44.
Mehta P, Reddivari AKR. Hepatitis. PubMed. 2022.
45.
Kedia S, Bhatt VR, Rajan SK, Tandra PK, Behery RAE, Akhtari M. Benign and malignant hematological manifestations of chronic hepatitis C virus infection. Int J Prev Med. 2014;5(Suppl 3):S179.PubMedPubMedCentral
46.
Cacoub P, Poynard T, Ghillani P, Charlotte F, Olivi M, Charles Piette J, et al. Extrahepatic manifestations of chronic hepatitis C. Arthritis Rheum. 1999;42(10):2204–12.PubMedCrossRef
47.
48.
Lee M-H, Yang H-I, Lu S-N, Jen C-L, You S-L, Wang L-Y, et al. Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study. J Infect Dis. 2012;206(4):469–77.PubMedCrossRef
49.
Sulkowski MS. Management of the hematologic complications of hepatitis C therapy. Clin Liver Dis. 2005;9(4):601–16.PubMedCrossRef
50.
51.
Kang J, Cho JH, Suh CW, Lee DH, Oh HB, Sohn YH, et al. High prevalence of hepatitis B and hepatitis C virus infections in Korean patients with hematopoietic malignancies. Ann Hematol. 2010;90(2):159–64.PubMedCrossRef
52.
Dal Maso L, Franceschi S. Hepatitis C virus and risk of lymphoma and other lymphoid neoplasms: a meta-analysis of epidemiologic studies. Cancer Epidemiol Biomark Prev. 2006;15(11):2078–85.CrossRef
53.
Rios A. HIV-related hematological malignancies: a concise review. Clin Lymphoma Myeloma Leuk. 2014;14:S96–103.PubMedCrossRef
54.
Kieny MP. Structure and regulation of the human AIDS virus. JAIDS J Acquired Immune Deficiency Syndromes. 1990;3(4):395–402.
55.
56.
57.
Coyle TE. Hematologic complications of human immunodeficiency virus infection and the acquired immunodeficiency syndrome. Med Clinics. 1997;81(2):449–70.
58.
Jacobson DL, McCutchan JA, Spechko PL, Abramson I, Smith RS, Bartok A, et al. The evolution of lymphadenopathy and hypergammaglobulinemia are evidence for early and sustained polyclonal B lymphocyte activation during human immunodeficiency virus infection. J Infect Dis. 1991;163(2):240–6.PubMedCrossRef
59.
Little RF, Dunleavy K. Update on the treatment of HIV-associated hematologic malignancies. Hematology 2013, the American Society of Hematology Education Program Book. 2013;2013(1):382–8.
60.
Kimani SM, Painschab MS, Horner M-J, Muchengeti M, Fedoriw Y, Shiels MS, et al. Epidemiology of haematological malignancies in people living with HIV. The Lancet HIV. 2020;7(9):e641–51.PubMedPubMedCentralCrossRef
61.
Carbone A, Vaccher E, Gloghini A. Hematologic cancers in individuals infected by HIV. Blood. 2022;139(7):995–1012.PubMedCrossRef
62.
63.
64.
Zhang L-l, Wei J-y, Wang L, Huang S-l, Chen J-l. Human T-cell lymphotropic virus type 1 and its oncogenesis. Acta Pharmacologica Sinica. 2017;38(8):1093–103.
65.
Human T-lymphotropic virus type 1. wwwwhoint.
66.
Caskey MF, Morgan DJ, Porto AF, Giozza SP, Muniz AL, Orge GO, et al. Clinical manifestations associated with HTLV type I infection: a cross-sectional study. AIDS Res Hum Retroviruses. 2007;23(3):365–71.PubMedCrossRef
67.
68.
69.
Majorovits E, Nejmeddine M, Tanaka Y, Taylor GP, Fuller SD, Bangham CR. Human T-lymphotropic virus-1 visualized at the virological synapse by electron tomography. PLoS ONE. 2008;3(5): e2251.PubMedPubMedCentralCrossRef
70.
Bindhu M, Nair A, Lairmore MD. Role of accessory proteins of HTLV-1 in viral replication, T cell activation, and cellular gene expression. Front Biosci. 2004;9:2556–76.PubMedCrossRef
71.
72.
Mazurov D, Ilinskaya A, Heidecker G, Lloyd P, Derse D. Quantitative comparison of HTLV-1 and HIV-1 cell-to-cell infection with new replication dependent vectors. PLoS Pathog. 2010;6(2): e1000788.PubMedPubMedCentralCrossRef
73.
74.
75.
76.
Del Valle DM, Kim-Schulze S, Huang HH, Beckmann ND, Nirenberg S, Wang B, et al. An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat Med. 2020;26(10):1636–43.PubMedPubMedCentralCrossRef
77.
78.
79.
80.
Haznedaroglu I, Malkan U. Local bone marrow renin-angiotensin system in the genesis of leukemia and other malignancies. Eur Rev Med Pharmacol Sci. 2016;20(19):4089–111.PubMed
81.
Gur I, Giladi A, Isenberg YN, Neuberger A, Stern A. COVID-19 in patients with hematologic malignancies: clinical manifestations, persistence, and immune response. Acta Haematol. 2022;145(3):297–309.PubMedCrossRef
Metadata
Title
Investigating the correlation between prominent viruses and hematological malignancies: a literature review
Authors
Arian Haghtalab
Milad Hejazi
Naeem Goharnia
Ali Yekanlou
Kousha Hazhir
Asma Barghi
Zahra Bazzaz
Iman Allahverdizadeh
Ataollah GhalibafSabbaghi
Publication date
01-05-2024
Publisher
Springer US
Published in
Medical Oncology / Issue 5/2024
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-024-02345-1

Other articles of this Issue 5/2024

Medical Oncology 5/2024 Go to the issue

Review Article

Liver cancer wars: plant-derived polyphenols strike back

Original Paper

Investigation of cellular communication and signaling pathways in tumor microenvironment for high TP53-expressing osteosarcoma cells through single-cell RNA sequencing

Original Paper

Structure-based multitargeted docking screening, pharmacokinetics, DFT, and dynamics simulation studies reveal mitoglitazone as a potent inhibitor of cellular survival and stress response proteins of lung cancer

Original Paper

Exploring the combined anti-cancer effects of sodium butyrate and celastrol in glioblastoma cell lines: a novel therapeutic approach

Original Paper

Chlordiazepoxide against signalling, receptor and regulatory proteins of breast cancer: a structure-based in-silico approach

Original Paper

Probiotic-derived silver nanoparticles target mTOR/MMP-9/BCL-2/dependent AMPK activation for hepatic cancer treatment
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits